⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1577316 | 1.00 | — | — | |
| SCHEMBL289079 | 0.79 | — | — | |
| SCHEMBL29503957 | 0.79 | — | — | |
| SCHEMBL502594 | 0.79 | — | — | |
| SCHEMBL29751880 | 0.79 | — | — | |
| SCHEMBL3370156 | 0.77 | — | — | |
| SCHEMBL22866663 | 0.77 | HTT (0.40) | — | |
| SCHEMBL22866664 | 0.77 | HTT (0.40) | — | |
| SCHEMBL15674471 | 0.77 | CYP11B1 (0.39) | — | |
| SCHEMBL2300183 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709373-A2 | HETEROCYCLIC COMPOUNDS FOR IMAGING AGGREGATED TAU IN TAUOPATHIES | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| CN-119707982-A | Pyrimidopyrazoles, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119677716-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119630670-A | Modulators of TNFalpha activity and uses thereof | 瑞雷拉公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2025043191-A1 | PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE | ORIC PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-119192140-A | Compounds as Kif18A inhibitors | 江苏星盛新辉医药有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-119118872-A | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024233875-A2 | HETEROCYCLIC COMPOUNDS FOR IMAGING AGGREGATED TAU IN TAUOPATHIES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-115298165-A | Tetralin and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-11485738-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-11-01 | — | — | US | disclosed |
| CN-115108972-A | Synthetic method of 2-methyl-3-fluoro-5-bromopyridine | 北京迪泰医药科技有限公司 | 2022-09-27 | — | — | CN | disclosed |
| EP-4043466-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114728168-A | Triazolecarbamate pyridylsulfonamides as LPA receptor antagonists and their use | 吉利德科学公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-110483521-B | Reversible covalent Bruton's tyrosine kinase inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114555620-A | Novel galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3746446-B1 | PRC2 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-110582495-B | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114269748-A | Imidazo [1,2-c ] pyrimidine derivatives as PRC2 inhibitors for the treatment of cancer | 米拉蒂医疗股份有限公司 | 2022-04-01 | — | — | CN | disclosed |